Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer
<p>The growing use of neoadjuvant chemotherapy to treat advanced stage high-grade serous ovarian cancer (HGSOC) creates an opportunity to better understand chemotherapy-induced mutational and gene expression changes. Here we performed a cohort study including 34 patients with advanced stage II...
Main Authors: | Javellana, M, Eckert, MA, Heide, J, Zawieracz, K, Weigert, M, Ashley, S, Stock, E, Chapel, D, Huang, L, Yamada, SD, Ahmed, AA, Lastra, RR, Chen, M, Lengyel, E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for Cancer Research
2021
|
Similar Items
-
The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
by: Mark A. Eckert, et al.
Published: (2021-06-01) -
Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
by: Ami Patel, et al.
Published: (2021-02-01) -
Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
by: M. K. Ibragimova, et al.
Published: (2022-03-01) -
Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
by: M. Liontos, et al.
Published: (2021-11-01) -
Neoadjuvant chemotherapy for advanced ovarian cancer: literature data and in vitro studies
by: S. A. Kuznetsov, et al.
Published: (2015-09-01)